Sunitinib has been shown to be effective for malignant PGLs, especially in carriers of the SDHB mutation.[17] In a recent review including all cases of malignant PGL treated with sunitinib therapy, sunitinib was demonstrated to be effective in 72.2% of the 36 patients.[18] In our review, 1 patient that received sunitinib for malignant CBT management achieved disease stabilization. This evidence concerns the gene SDHB and cancer.